Interviews

Cameron J. Turtle, MD, PhD, from the Fred Hutchinson Cancer Research Center, discusses the design of a chimeric antigen receptor (CAR).

Torsten O. Nielsen, MD, PhD, FRCPC, professor, pathology, University of British Columbia, discusses Ki67 in breast cancer.

Richard Finn, MD, from UCLA, discusses the treatment of patients with estrogen receptor-positive (ER+) breast cancer with antiestrogens.

Antoni Ribas, MD, PhD, the director of the Tumor Immunology Program Area at UCLA's Jonsson Comprehensive Cancer Center, discusses PD-1 and PD-L1 in various cancers.

Robert Andtbacka, MD, from the University of Utah School of Medicine and Huntsman Cancer Institute, discusses a trial analyzing talimogene laherparepvec (T-VEC) in melanoma.

Richard Finn, MD, from the Jonsson Comprehensive Cancer Center, UCLA, describes the development of cyclin-dependent kinases (CDKs) for the treatment of cancer.

Andre Goy, MD, from John Theurer Cancer Center, discusses recent research into fighting cancer with the immune system.

Suresh S. Ramalingam, MD, from the Winship Cancer Institute, discusses the investigation of the heat shock protein 90 inhibitor ganetespib as a treatment for patients with advanced lung cancer.

Marcia Brose, MD, PhD, from the University of Pennsylvania, on repurposing drugs to treat thyroid cancer.

Krishnansu S. Tewari, MD, from the University of California, Irvine, comments on the next steps for bevacizumab for recurrent cervical cancer.

Clifford A. Hudis, MD, describes ASCO's CancerLinQ program, which is a direct response to the Insitute of Medicine's call for rapid learning systems.

Richard D. Carvajal, MD, describes the design of a phase II study of selumetinib versus temozolomide in gnaq/Gna11 mutant uveal melanoma.

Emiel J. Rutgers, MD, from the Netherlands Cancer Institute, describes the personalization of treatment for patients with early-stage breast cancer.

Jane E. Churpek, MD, describes the BROCA genetic assay, uses targeted genomic capture and next-generation sequencing to analyze a panel of 42 genes.

Howard L. Kaufman, MD, Rush University Medical Center, comments on the changing outlook for immunotherapies.

Ellen T. Matloff, MS, CGC, discusses genetic testing, counseling, and the implications of the US Supreme Court decision to ban the patenting of genes.

Richard G. Gray, MA, MSc, discusses results from the randomized, phase III aTTom study that examined 10 years of tamoxifen versus the more standard 5 years.

D. Ross Camidge, MD, PhD, from the University of Colorado Cancer Center, comments on ALK-positive lung cancer patients with low testosterone.

Mario Sznol, MD, from the Yale Cancer Center, discusses the long-term follow-up results from a phase I trial investigating the anti-PD-1 monoclonal antibody nivolumab.

Nicholas J. Vogelzang, MD, from the University of Nevada School of Medicine, gives an overview of combining radium-223 with other agents for the treatment of prostate cancer.

Andreas du Bois, MD, discusses the background, rationale, and results for the exploration of maintenance pazopanib as a treatment for patients with advanced ovarian cancer.

A. Oliver Sartor, MD, Director of the Tulane Cancer Center, discusses the recent progress for the treatment of prostate cancer.

Alice T. Shaw, MD, PhD, describes a trial comparing crizotinib and chemotherapy in patients with advanced ALK-positive non-small cell lung cancer.

Mark R. Gilbert, MD, reviews the trial design and findings from the RTOG 0825 phase III trial evaluating bevacizumab in patients with newly diagnosed glioblastoma.

Edward Bradley, MD, gives an overview of the mechanism of action and development of moxetumomab pasudotox, a monoclonal antibody directed at CD22.

Julian Adams, PhD, President, Research and Development, Infinity Pharmaceuticals, describes a phase I trial of IPI-145, a potent inhibitor of PI3KEδ and PI3K-γ.

Richard L. Schilsky, MD, from University of Chicago Comprehensive Cancer Center, explains the benefit to generic drug user fees.

Richard Finn, MD, comments on the future of palbociclib (PD 0332991), a novel oral selective inhibitor of cyclin-dependent kinase 4/6 (CDK 4/6), for the treatment of breast cancer.

Sandra Swain, MD, from the Washington Cancer Institute at MedStar Washington Hospital Center, on the practice-changing information from the 2013 ASCO Meeting.

Antoni Ribas, MD, PhD, comments on the efficacy of lambrolizumab, an anti-PD-1 antibody, in patients with advanced melanoma.